- Home
- REE vs NRBO Comparison
REE vs NRBO Comparison
Compare REE & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- NRBO
- Stock Information
- Founded
- REE 2011
- NRBO N/A
- Country
- REE Israel
- NRBO United States
- Employees
- REE N/A
- NRBO N/A
- Industry
- REE Auto Manufacturing
- NRBO Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- NRBO Health Care
- Exchange
- REE Nasdaq
- NRBO Nasdaq
- Market Cap
- REE 52.8M
- NRBO 45.4M
- IPO Year
- REE N/A
- NRBO N/A
- Fundamental
- Price
- REE $6.18
- NRBO $3.40
- Analyst Decision
- REE Buy
- NRBO Strong Buy
- Analyst Count
- REE 4
- NRBO 1
- Target Price
- REE $9.25
- NRBO $10.00
- AVG Volume (30 Days)
- REE 767.5K
- NRBO 35.6K
- Earning Date
- REE 09-26-2024
- NRBO 11-11-2024
- Dividend Yield
- REE N/A
- NRBO N/A
- EPS Growth
- REE N/A
- NRBO N/A
- EPS
- REE N/A
- NRBO N/A
- Revenue
- REE $1,768,000.00
- NRBO N/A
- Revenue This Year
- REE $31,642.54
- NRBO N/A
- Revenue Next Year
- REE N/A
- NRBO N/A
- P/E Ratio
- REE N/A
- NRBO N/A
- Revenue Growth
- REE N/A
- NRBO N/A
- 52 Week Low
- REE $2.30
- NRBO $2.90
- 52 Week High
- REE $8.43
- NRBO $6.75
- Technical
- Relative Strength Index (RSI)
- REE 76.84
- NRBO 41.85
- Support Level
- REE $2.91
- NRBO $3.33
- Resistance Level
- REE $3.68
- NRBO $4.32
- Average True Range (ATR)
- REE 0.50
- NRBO 0.35
- MACD
- REE 0.29
- NRBO -0.00
- Stochastic Oscillator
- REE 85.16
- NRBO 16.36
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is developing REEcorner technology which packs critical vehicle components into a single compact module positioned between the chassis and the wheel as well as building commercial Electric Vehicles (EV) leveraging REEcorner technology. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.